Prospective homebuyers are facing higher costs to finance a home with the average long-term U.S. mortgage rate moving above 7% this week to its highest level in nearly five months
Shares of Metropolitan Bank Holding rose late Thursday after the company’s profit in the first quarter topped estimates.
Sometimes, you have to act while the tea is hot. For Roivant CEO Matt Gline, that meant dealing out Telavant to Roche for $7.1 billion last year, even if he wasn’t quite ready to let the vant company go.
The FDA has granted a de novo clearance to an artificial intelligence program capable of reading a standard brain MRI scan and predicting a patient’s chances of progressing from mild cognitive impairment and early memory loss to Alzheimer’s disease and dementia within five years, according to the software’s developer Darmiyan.
In mid-2021, after a decade of R&D, Neuralace Medical earned FDA clearance for its Axon Therapy, a noninvasive treatment option for chronic pain caused by nerve damage. The road to its next regulatory nod was much shorter: Less than three years later, the system now has a green light for use in treating nerve pain associated with diabetes, too.
Researchers have chipped away a little more at the mystery of cancer resistance, this time in the form of new findings that explain how the immune system senses DNA damage in precancerous cells.
Reuters and The Wall Street Journal have punctured investors’ hopes that Novartis will buy Cytokinetics. Both outlets have reported that the Swiss drugmaker is backing away from the potential deal late in negotiations, deflating the biotech’s share price.
After rolling out not one but two major DNA sequencing machine launches this past year, Pacific Biosciences has put forward massive gains in its quarterly and annual revenues.
Takeda turned heads at the tail end of 2022 when it announced a $4 billion acquisition of Nimbus Therapeutics’ tyrosine kinase 2 med, now known as TAK-279, throwing the Japanese company squarely in the middle of a hotly-contested immunology battle with Bristol Myers Squibb’s Sotyktu.
After inking a deal worth up to $75 million to acquire joint pain devicemaker Vyrsa Technologies late last year, Nevro now appears to be trying to lessen the impact of those costs on its bottom line. The neurostim developer laid out plans this week to lay off a total of 63 workers, comprising about 5% of its workforce.
Weekly Market Review – April 20, 2024
Alto Neuroscience preps IPO to push precision psychiatry therapies through the clinic
Machine learning hunt finds hundreds of new cancer targets, many with biomarkers to boot
ResMed’s warning on CPAP magnet interference earns FDA Class I recall tag
Illumina Ventures launches refreshed genomics startup accelerator program
LegoChem, riding ADC sugar rush, raises $411M from confectionery company
Allakos drops lead asset after midphase flops join litany of letdowns, halves headcount
AbbVie-backed Disco gets down with €20M to find new targets for antibody-based therapies
Roche’s pharma BD chief explains renewed ADC interest but is spoilt for choice
The Number of Americans Applying for Jobless Benefits Holds Steady as Labor Market Remains Strong
